<DOC>
	<DOCNO>NCT00584493</DOCNO>
	<brief_summary>The purpose study provide access CP-675,206 patient advance unresectable melanoma potential gain benefit treatment eligible participation CP-675,206 study .</brief_summary>
	<brief_title>Treatment Use Study Advanced Melanoma .</brief_title>
	<detailed_description>This expand access trial cancel prior enrol patient .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Advanced melanoma life expectancy least 6 month . Melanoma must consider unresectable . Patients stable , treated brain mets must stable clinically radiographically steroids least one month . Patients must eligible participation ongoing CP675,206 clinical study currently open enrollment . History chronic inflammatory autoimmune disease . History inflammatory bowel disease , celiac disease , chronic gastrointestinal condition associate diarrhea , active colitis , history diverticulitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>